Showing results (521-530 of 542) with videos related to
Sort By:
Pageof 55
Lancet (London, England)|February 16, 2019
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort studyFabrice Carrat, Hélène Fontaine, Céline Dorival, et al.Journal of Hepatology|February 28, 2025
Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosisPierre Nahon, Clovis Lusivika-Nzinga, Philippe Merle, et al.JHEP Reports : Innovation in Hepatology|July 24, 2024
Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohortVictor de Lédinghen, Claire Fougerou-Leurent, Estelle Le Pabic, et al.Clinics and Research in Hepatology and Gastroenterology|April 30, 2021
Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort studyLaurent Lam, Hélène Fontaine, Marc Bourliere, et al.Journal of Viral Hepatitis|November 1, 2018
Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohortSegolene Brichler, Pierre Nahon, Fabien Zoulim, et al.Gut|March 27, 2020
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre studyMinseok Albert Kim, Seung Up Kim, Dong Hyun Sinn, et al.Journal of Hepatology|May 15, 2013
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890Christophe Hézode, Hélène Fontaine, Céline Dorival, et al.Hepatology (Baltimore, Md.)|June 28, 2016
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)Nathalie Ganne-Carrié, Richard Layese, Valérie Bourcier, et al.Gastroenterology|April 8, 2014
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosisChristophe Hézode, Helene Fontaine, Celine Dorival, et al.Hepatology (Baltimore, Md.)|February 14, 2015
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, et al.Pageof 55